MediPharm Posts Q1 2021 Results: What Cannabis Stock Investors Need To Know

Comments
Loading...

MediPharm Labs Corp. LABS MEDIF MLZ reported Monday its first-quarter revenue amounted to CA$5.49 million ($4.53 million), down by roughly 9% sequentially and 50% year-over-year.

Adjusted EBITDA, a non-IFRS measure, came in negative at roughly CA$6.16 million, representing an improvement from a CA$8.77 million loss in the prior quarter and a loss of CA$5.66 million in the same quarter of 2020.

Greg Hunter, CFO of the Barrie, Ontario-based company, called the quarter a "cross-over period to our future state as the preferred global cannabis API provider to medical and wellness markets."

Q1 2021 Highlights

  • Gross profit was negative at CA$680 000 compared to a negative gross profit of CA$24.7 million in the previous quarter and CA$10.9 million in the same period of 2020.
  • A negative gross margin was 12%, compared to a negative gross margin of 408% in the last three months of 2020 and 98% in the prior year's corresponding quarter.
  • Net loss amounted to approximately CA$13.9 million, after shrinking by 55% sequentially and 37% year-over-year.
  • International sales rose to CA$1.8 million over the last three months of 2020, to CA$2.1 million in the first quarter of 2021.
  • The company achieved more than CA$1.5 million in cost savings.
  • As of March 31, the company had CA$42.1 million in cash and cash equivalents.

"We commenced 2021 focused on establishing our presence as a pharmaceutical company while ramping up and significantly growing our international sales," Hunter added.

In October, MediPharm Labs inked a deal to supply GMP-certified medical cannabis products to German pharmaceutical giant Stada Arzneimittel AG.

Six months later, in April, the company expanded its reach in the German market by signing a two-year supply agreement with the subsidiary of the multi-country medical and recreational cannabis operator IM Cannabis IMCC IMCC, which agreed to expand its product offering in Germany in 2021.

Photo by Diyahna Lewis on Unsplash

IMCC Logo
IMCCIM Cannabis Corp
$1.46-1.71%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
14.05
Growth
9.98
Quality
-
Value
35.47
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:

Cannabis is evolving—don’t get left behind!

Curious about what’s next for the industry and how to stay ahead in today’s competitive market?

Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.

Secure your spot now before prices go up—this is where the biggest deals and connections happen!

Get your tickets today!